

ALASKA  
**COVID-19**  
**VACCINE TASK FORCE**

**Review of Available Literature Related to COVID-19 Vaccine  
Development in U.S., Updated December 10, 2020**

<http://covidvax.alaska.gov>

**Clinical and Preclinical Trials**

Phase 1 trial, Moderna/NIH mRNA vaccine

<https://www.nejm.org/doi/full/10.1056/NEJMoa2022483?query=TOC>

Interim results, Moderna/NIH mRNA vaccine:

<https://www.nejm.org/doi/full/10.1056/NEJMc2032195>

Phase 1&2 trial, Pfizer/Biontech mRNA vaccine:

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31604-4/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext)

Preclinical trial (primates), Johnson & Johnson adenovirus-vectored vaccine:

<https://www.nature.com/articles/s41586-020-2607-z>.

Phase 1 and 2 trial (preprint), Johnson & Johnson adenovirus-vectored vaccine:

<https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1>

Preclinical trial (primates), AstraZeneca/Oxford adenovirus-vectored vaccine:

<https://www.nature.com/articles/s41586-020-2608-y>

Phase 2 trial, AstraZeneca/Oxford adenovirus-vectored vaccine:

[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)32466-1/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext)

Preliminary Phase 3 trial results, AstraZeneca/Oxford adenovirus-vectored vaccine:

<https://marlin-prod.literatumonline.com/pb-assets/Lancet/pdfs/S0140673620326611.pdf>

**Study Protocols**

The Moderna vaccine's study protocol:

<https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf>

The Pfizer vaccine's study protocol:

[https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001\\_Clinical\\_Protocol\\_0.pdf](https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-09/C4591001_Clinical_Protocol_0.pdf)

ALASKA  
**COVID-19**  
**VACCINE TASK FORCE**

**Review of Available Literature Related to COVID-19 Vaccine  
Development in U.S., Updated December 10, 2020**

<http://covidvax.alaska.gov>

**Press Releases and Investor Presentations**

Moderna/NIH mRNA vaccine:

<https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy>

Pfizer/Biontech mRNA vaccine:

[https://cdn.ymaws.com/www.immunizationmanagers.org/resource/collection/C51290B5-3749-4FC1-8F88-330CF4266E05/BNT162b2\\_Topline\\_IA\\_Readout\\_Press\\_Release\\_FINAL.pdf](https://cdn.ymaws.com/www.immunizationmanagers.org/resource/collection/C51290B5-3749-4FC1-8F88-330CF4266E05/BNT162b2_Topline_IA_Readout_Press_Release_FINAL.pdf)

<https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization>

Investor presentation:

[https://s21.q4cdn.com/317678438/files/doc\\_presentations/2020/09/Covid-19-Programs\\_FINAL.pdf](https://s21.q4cdn.com/317678438/files/doc_presentations/2020/09/Covid-19-Programs_FINAL.pdf)

Investor commentary:

<https://www.fiercepharma.com/vaccines/pfizer-sees-mostly-mild-to-moderate-safety-profile-phase-3-covid-vaccine-study>

AstraZeneca/Oxford adenovirus-vectored vaccine press release on phase 3 results:

<https://www.reuters.com/article/uk-health-coronavirus-astrazeneca-oxford/decades-of-work-and-half-a-dose-of-fortune-drove-oxford-vaccine-success-idUKKBN2832NG>

Johnson & Johnson adenovirus-vectored vaccine phase 3 trials:

<https://clinicaltrials.gov/ct2/show/NCT04505722>

Novavax protein subunit vaccine announcement regarding plans to start a Phase 3 trial in the US [in November:](#)

<https://ir.novavax.com/news-releases/news-release-details/novavax-provides-phase-3-covid-19-vaccine-clinical-development>

ALASKA  
**COVID-19**  
**VACCINE TASK FORCE**

**Review of Available Literature Related to COVID-19 Vaccine  
Development in U.S., Updated December 10, 2020**

<http://covidvax.alaska.gov>

**More Information**

FDA's independent advisory committee VRBPAC will be meeting on December 10 and December 17. Information for those meetings can be found here:

- [December 10 meeting materials](#)
- [December 17 meeting materials](#)

[Alaska COVID-19 Vaccine Information](#)

[AK DHSS vaccine info for clinicians](#)

[Two-part series on vaccine development](#) and [current research](#)

[CDC general vaccine information](#)

[FDA statement on vaccine approval](#) and [guidance document for COVID-19 vaccine development](#)

[FDA definition of an EUA](#) and [EUA guidelines for a COVID-19 vaccine](#)

[CDC guidance for vaccination during a pandemic](#)

[The New York Times maintains a vaccine tracker for updates on vaccine status](#)

ASTHO's three page handout on the vaccine approval process:

<https://www.astho.org/COVID-19/COVID-19-Vaccine-Approval-Process-Overview/>

**Allocation References**

ACIP slides on allocation:

<https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/COVID-02-Dooling.pdf>

CDC vaccine recommendations process:

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations-process.html>

ACIP MMWRs on ethical principles of allocation

<https://www.cdc.gov/mmwr/volumes/69/wr/mm6947e3.htm> and on Phase 1a allocation

[https://www.cdc.gov/mmwr/volumes/69/wr/mm6949e1.htm?s\\_cid=mm6949e1\\_w](https://www.cdc.gov/mmwr/volumes/69/wr/mm6949e1.htm?s_cid=mm6949e1_w)